Beam Therapeutics is a biotechnology company. Within its ex vivo platform, Co. has identified three development candidates. BEAM-101 reproduces single base changes seen in individuals with Hereditary Persistence of Fetal Hemoglobin to potentially protect them from the effects of mutations causing sickle cell disease or beta thalassemia. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. The BEAM stock yearly return is shown above.
The yearly return on the BEAM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BEAM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|